← Back to Search

Alkylating agents

Combination Chemotherapy for Rhabdomyosarcoma

Phase 3
Recruiting
Led By Wendy Allen-Rhoades
Research Sponsored by Children's Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/gender criteria
Patients must be =< 50 years of age at the time of enrollment
Must not have
Patients with central nervous system involvement of RMS
Patients who have received any chemotherapy (excluding steroids) and/or radiation therapy for RMS prior to enrollment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years from study enrollment
Awards & highlights

Summary

This trial is testing a new cancer treatment for patients with high risk rhabdomyosarcoma. The treatment is a combination of 4 drugs, and the trial will test if it is more effective than the current standard of care.

Who is the study for?
This trial is for patients up to 50 years old with high-risk rhabdomyosarcoma (RMS), including embryonal and alveolar types, but not adult-type pleomorphic. Eligible participants must have newly diagnosed RMS, meet specific stage and group criteria, have a certain kidney function level, normal bilirubin levels unless obstructed by tumor, and provide informed consent. Pregnant or breastfeeding women are excluded as well as those with uncontrolled infections or central nervous system involvement of RMS.Check my eligibility
What is being tested?
The study tests the addition of vinorelbine to standard chemotherapy (vincristine, dactinomycin, cyclophosphamide) in treating high-risk RMS. It also examines maintenance therapy post-chemotherapy to see if it helps eliminate cancer or prevent its return. The medications used aim to stop cancer cell growth by damaging their DNA.See study design
What are the potential side effects?
Chemotherapy drugs like vinorelbine can cause side effects such as nausea, hair loss, fatigue, low blood counts leading to infection risk or bleeding problems; vincristine may cause nerve damage; dactinomycin might lead to mouth sores; cyclophosphamide could result in bladder irritation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidney function is normal or near normal.
Select...
I am 50 years old or younger.
Select...
My bilirubin levels are within the normal range for my age.
Select...
My cancer has spread to my bone marrow, confirmed by specific staining tests.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My cancer has spread to my brain or spinal cord.
Select...
I have not had chemotherapy or radiation for RMS before joining.
Select...
I do not have any untreated infections.
Select...
My RMS is a second cancer, previously treated with chemo or radiation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years from study enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years from study enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Event-free survival
Secondary outcome measures
Feasibility and safety assessed by the adverse events, toxicities and treatment delays
Incidence of adverse events
Overall survival
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm B (vinorelbine, VAC, VINO-CPO)Experimental Treatment13 Interventions
Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1 and 8, vincristine sulfate IV on day 15, dactinomycin IV over 1-15 minutes or IVP over 1-5 minutes on day 1 of cycles 1-5 and 8-14, and cyclophosphamide IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on weeks 13 and 40. MAINTENANCE: Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1, 8, and 15, and cyclophosphamide PO on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients in both arms undergo CT, MRI, PET, x-ray imaging, and/or bone scan, as well as blood sample collection throughout the trial. Patients may also undergo bone marrow aspiration and/or biopsy as clinically indicated.
Group II: Arm A (VAC, VINO-CPO)Experimental Treatment13 Interventions
Patients receive vincristine sulfate IV on days 1, 8 and 15 of cycles 1-4, 7, 8, 11, and 12, and day 1 of cycles 5, 6, 9, 10, 13, and 14. Patients also receive dactinomycin IV over 1-15 minutes or IVP over 1-5 minutes on day 1 of cycles 1-5, 8-10, and 11-14, and cyclophosphamide IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on weeks 13 and 40. MAINTENANCE: Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1, 8, and 15, and cyclophosphamide PO on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients in both arms undergo CT, MRI, PET, x-ray imaging, and/or bone scan, as well as blood sample collection throughout the trial. Patients may also undergo bone marrow aspiration and/or biopsy as clinically indicated.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dactinomycin
2010
Completed Phase 3
~1310
Radiation Therapy
2017
Completed Phase 3
~7250
Positron Emission Tomography
2008
Completed Phase 2
~2210
Cyclophosphamide
1995
Completed Phase 3
~3770
Magnetic Resonance Imaging
2017
Completed Phase 3
~1160
Vinorelbine Tartrate
2010
Completed Phase 3
~670
Biospecimen Collection
2004
Completed Phase 2
~1720
Bone Marrow Aspiration
2011
Completed Phase 2
~1740
Bone Marrow Biopsy
2021
Completed Phase 2
~10
Bone Scan
2015
Completed Phase 2
~50
Computed Tomography
2017
Completed Phase 2
~2720
Vincristine Sulfate
2005
Completed Phase 3
~10160

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,748 Previous Clinical Trials
40,959,283 Total Patients Enrolled
87 Trials studying Rhabdomyosarcoma
11,727 Patients Enrolled for Rhabdomyosarcoma
Children's Oncology GroupLead Sponsor
456 Previous Clinical Trials
239,669 Total Patients Enrolled
35 Trials studying Rhabdomyosarcoma
5,779 Patients Enrolled for Rhabdomyosarcoma
Wendy Allen-RhoadesPrincipal InvestigatorChildren's Oncology Group

Media Library

Cyclophosphamide (Alkylating agents) Clinical Trial Eligibility Overview. Trial Name: NCT04994132 — Phase 3
Rhabdomyosarcoma Research Study Groups: Arm B (vinorelbine, VAC, VINO-CPO), Arm A (VAC, VINO-CPO)
Rhabdomyosarcoma Clinical Trial 2023: Cyclophosphamide Highlights & Side Effects. Trial Name: NCT04994132 — Phase 3
Cyclophosphamide (Alkylating agents) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04994132 — Phase 3
~62 spots leftby Sep 2027